Pfizer's ELREXFIO hits Phase 3 win in myeloma trial

The MagnetisMM-32 readout gives Pfizer a statistically significant progression-free survival benefit for ELREXFIO in a patient group whose disease has already progressed after anti-CD38 therapy and lenalidomide. That positioning matters because it points to use earlier in the treatment journey rather than only after multiple prior regimens.

The trial compared ELREXFIO head to head against three established regimens in this relapsed or refractory setting, and the body reports that more than 75% of patients had not experienced disease progression or death at the analysis cut. Pfizer now has data it can take to regulators for a potential label expansion; whether that translates into a broader multiple myeloma opportunity depends on the submission and review, which the body frames as a condition rather than a certainty.

Separately, Pfizer entered a new R&D partnership with Edison Scientific to deploy the Edison AI Platform and Kosmos across its research pipeline. That deal connects to the company's existing emphasis on AI-assisted research and cost savings, though the body notes that core risks around drug pricing and pipeline setbacks remain in place.